Review



human muc6 orf  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    OriGene human muc6 orf
    Immunoprecipitation (IP) and Western blotting analysis of αGlcNAc, α4GnT, and <t>MUC6</t> expression. Whole‐cell lysates (WCL; bottom five rows) and IP products (top three rows) from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoblotted with antibodies shown on the left side of the figure. *, unglycosylated MUC6; **, glycosylated MUC6. β‐actin serves as the loading control
    Human Muc6 Orf, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human muc6 orf/product/OriGene
    Average 92 stars, based on 4 article reviews
    human muc6 orf - by Bioz Stars, 2026-02
    92/100 stars

    Images

    1) Product Images from "Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy"

    Article Title: Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy

    Journal: Cancer Science

    doi: 10.1111/cas.15209

    Immunoprecipitation (IP) and Western blotting analysis of αGlcNAc, α4GnT, and MUC6 expression. Whole‐cell lysates (WCL; bottom five rows) and IP products (top three rows) from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoblotted with antibodies shown on the left side of the figure. *, unglycosylated MUC6; **, glycosylated MUC6. β‐actin serves as the loading control
    Figure Legend Snippet: Immunoprecipitation (IP) and Western blotting analysis of αGlcNAc, α4GnT, and MUC6 expression. Whole‐cell lysates (WCL; bottom five rows) and IP products (top three rows) from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoblotted with antibodies shown on the left side of the figure. *, unglycosylated MUC6; **, glycosylated MUC6. β‐actin serves as the loading control

    Techniques Used: Immunoprecipitation, Western Blot, Expressing, Transduction

    Effects of α4GnT and MUC6 expression on MIA PaCa‐2 and PANC‐1 cell proliferation. A, B, Anchorage‐dependent proliferation analysis. MIA PaCa‐2 (A) or PANC‐1 (B) cells transduced as indicated were seeded at 1 × 10 3 cells per well in 96‐well tissue culture plates, and an MTS assay was performed daily for 3 d. A cell proliferation ratio was calculated with the value on day 0 set to 1. C, D, Anchorage‐independent proliferation analysis. MIA PaCa‐2 (C) or PANC‐1 (D) cells transduced as indicated were seeded in poly‐HEMA–coated 96‐well plates and assayed using the same procedure described to assess anchorage‐dependent proliferation. Results are expressed as the mean (n = 6) and error bars indicate SD. Representative results from four independent experiments are shown. * P < .05 and ** P < .01
    Figure Legend Snippet: Effects of α4GnT and MUC6 expression on MIA PaCa‐2 and PANC‐1 cell proliferation. A, B, Anchorage‐dependent proliferation analysis. MIA PaCa‐2 (A) or PANC‐1 (B) cells transduced as indicated were seeded at 1 × 10 3 cells per well in 96‐well tissue culture plates, and an MTS assay was performed daily for 3 d. A cell proliferation ratio was calculated with the value on day 0 set to 1. C, D, Anchorage‐independent proliferation analysis. MIA PaCa‐2 (C) or PANC‐1 (D) cells transduced as indicated were seeded in poly‐HEMA–coated 96‐well plates and assayed using the same procedure described to assess anchorage‐dependent proliferation. Results are expressed as the mean (n = 6) and error bars indicate SD. Representative results from four independent experiments are shown. * P < .05 and ** P < .01

    Techniques Used: Expressing, MTS Assay

    Analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. A, B, Expression analysis of endogenous TFF2 (A) and C2GnT (B) in MIA PaCa‐2 and PANC‐1 cells. Whole‐cell lysates (WCLs) of AGS cells ectopically expressing TFF2 or C2GnT were used as a positive control (P). *, unglycosylated form of TFF2 or C2GnT; **, glycosylated form of TFF2 or C2GnT. β‐actin serves as the loading control. C, Immunoprecipitation (IP) and Western blotting analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. Culture supernatants from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoprecipitated and immunoblotted with antibodies shown in the figure. Nonspecific bindings to beads are indicated by arrows
    Figure Legend Snippet: Analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. A, B, Expression analysis of endogenous TFF2 (A) and C2GnT (B) in MIA PaCa‐2 and PANC‐1 cells. Whole‐cell lysates (WCLs) of AGS cells ectopically expressing TFF2 or C2GnT were used as a positive control (P). *, unglycosylated form of TFF2 or C2GnT; **, glycosylated form of TFF2 or C2GnT. β‐actin serves as the loading control. C, Immunoprecipitation (IP) and Western blotting analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. Culture supernatants from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoprecipitated and immunoblotted with antibodies shown in the figure. Nonspecific bindings to beads are indicated by arrows

    Techniques Used: Expressing, Positive Control, Immunoprecipitation, Western Blot, Transduction

    Correlation of A4GNT or MUC6 expression with prognosis of patients with pancreatic cancer. A, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low A4GNT expression. Red line indicates cases (n = 28) with high A4GNT expression, and black line indicates cases (n = 14) with low A4GNT expression. B, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low MUC6 expression. Red line indicates cases (n = 24) with high MUC6 expression, and black line indicates cases (n = 18) with low MUC6 expression. HR, hazard ratio
    Figure Legend Snippet: Correlation of A4GNT or MUC6 expression with prognosis of patients with pancreatic cancer. A, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low A4GNT expression. Red line indicates cases (n = 28) with high A4GNT expression, and black line indicates cases (n = 14) with low A4GNT expression. B, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low MUC6 expression. Red line indicates cases (n = 24) with high MUC6 expression, and black line indicates cases (n = 18) with low MUC6 expression. HR, hazard ratio

    Techniques Used: Expressing

    Schematic representation of the inhibitory effects of αGlcNAc and MUC6 on cellular motility and invasiveness. When MUC6 is ectopically expressed, cells are surrounded by MUC6, thus reducing motility and invasiveness. When αGlcNAc is attached to MUC6 by α4GnT, complexes of αGlcNAc‐bound MUC6 and TFF2 are formed, resulting in a more potent effect because the cells are surrounded by the highly viscous MUC6‐TFF2 complex. Yellow square, N ‐acetylgalactosamine (GalNAc); yellow circle, galactose (Gal); blue square, N ‐acetylglucosamine (GlcNAc)
    Figure Legend Snippet: Schematic representation of the inhibitory effects of αGlcNAc and MUC6 on cellular motility and invasiveness. When MUC6 is ectopically expressed, cells are surrounded by MUC6, thus reducing motility and invasiveness. When αGlcNAc is attached to MUC6 by α4GnT, complexes of αGlcNAc‐bound MUC6 and TFF2 are formed, resulting in a more potent effect because the cells are surrounded by the highly viscous MUC6‐TFF2 complex. Yellow square, N ‐acetylgalactosamine (GalNAc); yellow circle, galactose (Gal); blue square, N ‐acetylglucosamine (GlcNAc)

    Techniques Used:



    Similar Products

    human muc6 orf  (OriGene)
    92
    OriGene human muc6 orf
    Immunoprecipitation (IP) and Western blotting analysis of αGlcNAc, α4GnT, and <t>MUC6</t> expression. Whole‐cell lysates (WCL; bottom five rows) and IP products (top three rows) from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoblotted with antibodies shown on the left side of the figure. *, unglycosylated MUC6; **, glycosylated MUC6. β‐actin serves as the loading control
    Human Muc6 Orf, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human muc6 orf/product/OriGene
    Average 92 stars, based on 1 article reviews
    human muc6 orf - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Immunoprecipitation (IP) and Western blotting analysis of αGlcNAc, α4GnT, and MUC6 expression. Whole‐cell lysates (WCL; bottom five rows) and IP products (top three rows) from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoblotted with antibodies shown on the left side of the figure. *, unglycosylated MUC6; **, glycosylated MUC6. β‐actin serves as the loading control

    Journal: Cancer Science

    Article Title: Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy

    doi: 10.1111/cas.15209

    Figure Lengend Snippet: Immunoprecipitation (IP) and Western blotting analysis of αGlcNAc, α4GnT, and MUC6 expression. Whole‐cell lysates (WCL; bottom five rows) and IP products (top three rows) from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoblotted with antibodies shown on the left side of the figure. *, unglycosylated MUC6; **, glycosylated MUC6. β‐actin serves as the loading control

    Article Snippet: The human MUC6 ORF was excised from the TrueClone ORF Collection MUC6 (RC219711; OriGene Technologies) and subcloned into the pMXs‐IRES‐Bsd retroviral vector (Cell biolabs) by inserting an in‐flame C‐terminal Myc‐tag sequence.

    Techniques: Immunoprecipitation, Western Blot, Expressing, Transduction

    Effects of α4GnT and MUC6 expression on MIA PaCa‐2 and PANC‐1 cell proliferation. A, B, Anchorage‐dependent proliferation analysis. MIA PaCa‐2 (A) or PANC‐1 (B) cells transduced as indicated were seeded at 1 × 10 3 cells per well in 96‐well tissue culture plates, and an MTS assay was performed daily for 3 d. A cell proliferation ratio was calculated with the value on day 0 set to 1. C, D, Anchorage‐independent proliferation analysis. MIA PaCa‐2 (C) or PANC‐1 (D) cells transduced as indicated were seeded in poly‐HEMA–coated 96‐well plates and assayed using the same procedure described to assess anchorage‐dependent proliferation. Results are expressed as the mean (n = 6) and error bars indicate SD. Representative results from four independent experiments are shown. * P < .05 and ** P < .01

    Journal: Cancer Science

    Article Title: Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy

    doi: 10.1111/cas.15209

    Figure Lengend Snippet: Effects of α4GnT and MUC6 expression on MIA PaCa‐2 and PANC‐1 cell proliferation. A, B, Anchorage‐dependent proliferation analysis. MIA PaCa‐2 (A) or PANC‐1 (B) cells transduced as indicated were seeded at 1 × 10 3 cells per well in 96‐well tissue culture plates, and an MTS assay was performed daily for 3 d. A cell proliferation ratio was calculated with the value on day 0 set to 1. C, D, Anchorage‐independent proliferation analysis. MIA PaCa‐2 (C) or PANC‐1 (D) cells transduced as indicated were seeded in poly‐HEMA–coated 96‐well plates and assayed using the same procedure described to assess anchorage‐dependent proliferation. Results are expressed as the mean (n = 6) and error bars indicate SD. Representative results from four independent experiments are shown. * P < .05 and ** P < .01

    Article Snippet: The human MUC6 ORF was excised from the TrueClone ORF Collection MUC6 (RC219711; OriGene Technologies) and subcloned into the pMXs‐IRES‐Bsd retroviral vector (Cell biolabs) by inserting an in‐flame C‐terminal Myc‐tag sequence.

    Techniques: Expressing, MTS Assay

    Analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. A, B, Expression analysis of endogenous TFF2 (A) and C2GnT (B) in MIA PaCa‐2 and PANC‐1 cells. Whole‐cell lysates (WCLs) of AGS cells ectopically expressing TFF2 or C2GnT were used as a positive control (P). *, unglycosylated form of TFF2 or C2GnT; **, glycosylated form of TFF2 or C2GnT. β‐actin serves as the loading control. C, Immunoprecipitation (IP) and Western blotting analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. Culture supernatants from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoprecipitated and immunoblotted with antibodies shown in the figure. Nonspecific bindings to beads are indicated by arrows

    Journal: Cancer Science

    Article Title: Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy

    doi: 10.1111/cas.15209

    Figure Lengend Snippet: Analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. A, B, Expression analysis of endogenous TFF2 (A) and C2GnT (B) in MIA PaCa‐2 and PANC‐1 cells. Whole‐cell lysates (WCLs) of AGS cells ectopically expressing TFF2 or C2GnT were used as a positive control (P). *, unglycosylated form of TFF2 or C2GnT; **, glycosylated form of TFF2 or C2GnT. β‐actin serves as the loading control. C, Immunoprecipitation (IP) and Western blotting analysis of the αGlcNAc‐bound MUC6 and TFF2 complex. Culture supernatants from MIA PaCa‐2 or PANC‐1 cells transduced with MUC6, MUC6 / A4GNT, or control, as indicated, were immunoprecipitated and immunoblotted with antibodies shown in the figure. Nonspecific bindings to beads are indicated by arrows

    Article Snippet: The human MUC6 ORF was excised from the TrueClone ORF Collection MUC6 (RC219711; OriGene Technologies) and subcloned into the pMXs‐IRES‐Bsd retroviral vector (Cell biolabs) by inserting an in‐flame C‐terminal Myc‐tag sequence.

    Techniques: Expressing, Positive Control, Immunoprecipitation, Western Blot, Transduction

    Correlation of A4GNT or MUC6 expression with prognosis of patients with pancreatic cancer. A, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low A4GNT expression. Red line indicates cases (n = 28) with high A4GNT expression, and black line indicates cases (n = 14) with low A4GNT expression. B, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low MUC6 expression. Red line indicates cases (n = 24) with high MUC6 expression, and black line indicates cases (n = 18) with low MUC6 expression. HR, hazard ratio

    Journal: Cancer Science

    Article Title: Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy

    doi: 10.1111/cas.15209

    Figure Lengend Snippet: Correlation of A4GNT or MUC6 expression with prognosis of patients with pancreatic cancer. A, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low A4GNT expression. Red line indicates cases (n = 28) with high A4GNT expression, and black line indicates cases (n = 14) with low A4GNT expression. B, Kaplan‐Meier curves depicting survival time for patients with pancreatic ductal adenocarcinoma whose samples showed high or low MUC6 expression. Red line indicates cases (n = 24) with high MUC6 expression, and black line indicates cases (n = 18) with low MUC6 expression. HR, hazard ratio

    Article Snippet: The human MUC6 ORF was excised from the TrueClone ORF Collection MUC6 (RC219711; OriGene Technologies) and subcloned into the pMXs‐IRES‐Bsd retroviral vector (Cell biolabs) by inserting an in‐flame C‐terminal Myc‐tag sequence.

    Techniques: Expressing

    Schematic representation of the inhibitory effects of αGlcNAc and MUC6 on cellular motility and invasiveness. When MUC6 is ectopically expressed, cells are surrounded by MUC6, thus reducing motility and invasiveness. When αGlcNAc is attached to MUC6 by α4GnT, complexes of αGlcNAc‐bound MUC6 and TFF2 are formed, resulting in a more potent effect because the cells are surrounded by the highly viscous MUC6‐TFF2 complex. Yellow square, N ‐acetylgalactosamine (GalNAc); yellow circle, galactose (Gal); blue square, N ‐acetylglucosamine (GlcNAc)

    Journal: Cancer Science

    Article Title: Glycosylation of MUC6 by α1,4‐linked N ‐acetylglucosamine enhances suppression of pancreatic cancer malignancy

    doi: 10.1111/cas.15209

    Figure Lengend Snippet: Schematic representation of the inhibitory effects of αGlcNAc and MUC6 on cellular motility and invasiveness. When MUC6 is ectopically expressed, cells are surrounded by MUC6, thus reducing motility and invasiveness. When αGlcNAc is attached to MUC6 by α4GnT, complexes of αGlcNAc‐bound MUC6 and TFF2 are formed, resulting in a more potent effect because the cells are surrounded by the highly viscous MUC6‐TFF2 complex. Yellow square, N ‐acetylgalactosamine (GalNAc); yellow circle, galactose (Gal); blue square, N ‐acetylglucosamine (GlcNAc)

    Article Snippet: The human MUC6 ORF was excised from the TrueClone ORF Collection MUC6 (RC219711; OriGene Technologies) and subcloned into the pMXs‐IRES‐Bsd retroviral vector (Cell biolabs) by inserting an in‐flame C‐terminal Myc‐tag sequence.

    Techniques: